Alzheimer’s Can Now be Diagnosed Early; Thanks to Neurotrack

March 18, 2013, By Sanjeev Ramachandran

Prevention is always better than cure and if the disease doesn’t have a permanent cure discovered yet, it is absolutely better to find out about the disease before it strikes with full impact.

This is where the Neurotrack kick into action. Neurotrack’s technology can diagnose the onset of Alzheimer’s Disease three to four years before symptoms occur. Based on groundbreaking research, it enables pharmaceutical companies and researchers to recruit qualified candidates for clinical trials, and more effectively measure drug efficacy, speeding up drug discovery and development.

Neurotrack is also becoming the standard for early clinical screening of Alzheimer’s and dementia related disorders.


Alzheimer’s disease has always eluded scientists and physicians in terms of what causes the disease, how to detect and diagnose it, and how to treat it. It is like a mystery disease that pops out one day for a person.

The neurotrack methodology is pretty simple. You sit in front of a computer screen with an eye-tracking device and view a series of images, some novel and some not novel. Based on how much time you spend looking at the novel image versus the image that hasn’t changed, Neurotrack can give you a prognosis.

Neurotrack’s second product removes the need for the eye-tracker, making the test even more accessible and affordable for families and individuals around the globe. The redesigned test uses a mouse or trackpad.

A user can bring the images into focus using a viewport that is controlled by the mouse. The mouse movement is exactly correlated with eye movement and renders the same results.

One of the biggest problems that pharmaceutical companies face today in terms of developing preventive drugs for Alzheimer’s disease is populating the clinical trials with the right type of people; people who are pre-symptomatic but who we know for sure will convert to Alzheimer’s disease in the future.

So by making sure clinical trials have the right subjects, testing for new Alzheimer’s drugs and treatments can be made a lot better. Trials can be conducted more quickly, and life-saving drugs could get to market much faster.

Plus, for families, an extra few years to plan financially for Alzheimer’s can be a huge benefit. So yes, the cure can be made by using the Neurotrack methodology in the right quantity and quality as there will come a day when the Alzheimer’s disease will be erased from this world once and for all.

© 2008-2012 - All rights reserved | Privacy Policy